Community hub
0 subscribers8 pages, 0 posts
Recent from talks
All channels
Be the first to start a discussion here.
Be the first to start a discussion here.
Be the first to start a discussion here.
Be the first to start a discussion here.
Contribute something
Welcome to the community hub built to collect knowledge and have discussions related to Tradipitant.
Nothing was collected or created yet.
Tradipitant
View on Wikipediafrom Wikipedia
 | |
| Clinical data | |
|---|---|
| Trade names | Nereus |
| Other names | VLY-686, LY686017 |
| AHFS/Drugs.com | nereus |
| License data |
|
| Routes of administration | By mouth |
| Drug class | Neurokinin NK1 antagonist |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C28H16ClF6N5O |
| Molar mass | 587.91 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Tradipitant, sold under the brand name Nereus, is a medication used as prevention of vomiting induced by motion (motion sickness).[1] It is a neurokinin 1 receptor antagonist.[1] It works by blocking substance P, a small signaling molecule.[1] VLY-686 was purchased by Vanda Pharmaceuticals from Eli Lilly and Company in 2012.[2]
Tradipitant was approved for medical use in the United States in December 2025.[3]
Medical uses
[edit]Society and culture
[edit]Legal status
[edit]Tradipitant was approved for medical use in the United States in December 2025.[4]
Names
[edit]Tradipitant is the international nonproprietary name.[5]
Tradipitant is sold under the brand name Nereus.[1]
References
[edit]- ^ a b c d e f https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/220152Orig1s000lbl.pdf
- ^ "Company Overview of Eli Lilly & Co., Worldwide License to Develop and Commercialize VLY-686". Bloomberg Business. Retrieved 16 November 2015.
- ^ "Novel Drug Approvals for 2025". U.S. Food and Drug Administration (FDA). 2 January 2026. Retrieved 10 January 2026.
- ^ "Vanda Pharmaceuticals Announces FDA Approval of Nereus (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness" (Press release). Vanda Pharmaceuticals. 30 December 2025. Retrieved 10 January 2026 – via PR Newswire.
- ^ "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 73". WHO Drug Information. 29 (1). 2015. hdl:10665/331088.
External links
[edit]- "Tradipitant ( Code - C152707 )". EVS Explore.
- Clinical trial number NCT04327661 for "Motion Syros: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness" at ClinicalTrials.gov
- Clinical trial number NCT05903924 for "Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness" at ClinicalTrials.gov
 | This pharmacology-related article is a stub. You can help Wikipedia by adding missing information. |